AUSTIN, Texas, April 27, 2015 /PRNewswire/ -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today it will report first quarter 2015 financial results after the market close on Monday, May 11, 2015, followed by an investor conference call and webcast at 4:30pm Eastern.
Conference Call & Webcast: | |
Monday, May 11, 2015 at 4:30pm Eastern/1:30pm Pacific | |
Domestic: | 888-556-4997 |
International: | 719-457-2628 |
Conference ID: | 6696118 |
Webcast: http://public.viavid.com/player/index.php?id=114376 | |
Replay - Available through May 25, 2015 | |
Domestic: | 877-870-5176 |
International: | 858-384-5517 |
Conference ID: | 6696118 |
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, have diagnostic programs in gynecologic disease. The company’s lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
mwood@lifesciadvisors.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vermillion-to-report-first-quarter-2015-financial-results-and-host-investor-conference-call-on-may-11-300072034.html
SOURCE Vermillion, Inc.
Help employers find you! Check out all the jobs and post your resume.
